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Abstract
Background Statins are currently the preferred pharma-
cological therapy in individuals with familial hypercho-
lesterolemia (FH) with the aim to prevent premature
atherosclerosis. In adults, these agents have been proven to
be safe and well tolerated; however, non-adherence is a
significant clinical issue.
Objectives In this study, we evaluated tolerability and
adherence to statin therapy in young adult FH patients
10 years after this was initiated in their childhood.
Methods A questionnaire including items on medical
history, adherence and reasons for discontinuation was sent
to 214 young adult FH patients that initiated statin therapy
at least 10 years ago. Tolerability was defined as 100 %
minus the percentage of patients that discontinued statin
therapy due to side effects. Adherence was defined as the
extent to which patients took their medication as prescribed
by their physician. We labelled patients adherent if they
took 80 % or more of their pills in the month preceding our
assessment.
Results Follow-up was successful in 205 (95.8 %) sub-
jects (age 18–30 years). A history of side effects was
reported by 40 (19.5 %) of the patients, and mainly con-
sisted of muscle complaints and gastrointestinal symptoms.
Three patients (1.5 %) discontinued statin therapy because
of side effects. Rhadbomyolysis or other serious adverse
events were not reported. In fact, 169 (82.4 %) of 205
patients remained on statin treatment and 78.7 % (148 out
of 188) were adherent. None of the patient characteristics
were significantly associated with adherence.
Conclusions Individuals with FH who started statin
therapy in childhood demonstrated good adherence during
ten years of treatment. Furthermore, statin therapy was well
tolerated; only a small minority discontinued therapy
because of side effects and the side effects that were
reported were mild in nature.
Key Points
Subjects with familial hypercholesterolemia
continuing statin therapy since childhood showed
good adherence.
Only a small minority discontinued therapy because
of side effects and reported side effects were mild.
The results of our study suggest that early initiation
of statin therapy may contribute to habitual use of
medication despite its preventive character.
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1 Introduction
Familial hypercholesterolemia (FH), a common domi-
nantly inherited disorder of lipoprotein metabolism, is
characterized by severely elevated low-density lipoprotein
cholesterol (LDL-C) levels from birth onwards that pre-
dispose to premature atherosclerosis and subsequent car-
diovascular disease (CVD) [1, 2]. In order to protect FH
children from premature CVD, statins are currently the
preferred pharmacological therapy and are recommended
from the age of 8 years onwards [3, 4]. The efficacy of
statins in this patient group was recently underlined by the
results of a 10-year follow-up study in young adults with
FH that showed that long-term statin treatment was asso-
ciated with normalization of progression of the carotid
intima media thickness (cIMT), a marker of early athero-
sclerosis [5]. However, LDL-C levels of the majority of
patients in this study did not meet current treatment
standards.
Studies among middle-aged hypercholesterolemic
patients reported that a significant number do not achieve
LDL-C goals, mainly due to poor adherence to statin
therapy [6–8]. It could be hypothesized that young FH
patients might be even less adherent since several studies
among individuals with other chronic disorders reported
poor adherence during adolescence, a stage of life in which
both development and social context change simulta-
neously [9–11]. Furthermore, in FH individuals, young
patients are asymptomatic and less likely to perceive
themselves at risk for CVD, which could lead to poor
adherence. Lastly, statin intolerance, or the inability to use
statins because of side effects, might cause poor adherence
or even discontinuation of treatment.
Little is known about tolerability and adherence in
young FH patients and we therefore set out to study these
characteristics in a cohort of young adult FH patients after
10 years of statin therapy that was initiated in childhood.
Furthermore, we also examined the association between
patient characteristics and adherence. Here, we present our
results.
2 Methods
2.1 Study Population and Design
All 214 children who were randomized between 1997 and
1999 into a single-center, double-blind, placebo-controlled
trial, evaluating the efficacy and safety of pravastatin, were
eligible for the current study. The trial has been described
in detail elsewhere [5, 12]. Briefly, children were enrolled
in that study when they met the following criteria: one
parent with a definite clinical or molecular diagnosis of FH;
age between 8 and 18 years; at least 3 months on a fat-
restricted diet; two fasting samples with plasma LDL-C
levels C4.0 mmol/L and triglyceride levels \4.0 mmol/L;
adequate contraception in sexually active girls; and no drug
treatment for FH or use of plant sterols. Reasons for
exclusion were homozygous FH, hypothyroidism, and
abnormal plasma levels of muscle or liver enzymes. Chil-
dren were randomly assigned to receive either pravastatin
or placebo for 2 years. In the active treatment group,
children younger than 14 years of age received 20 mg of
pravastatin, and those aged 14 years or older received
40 mg daily. After the end of the placebo-controlled trial,
pravastatin was given to both treatment groups (\14 years:
20 mg, C14 years: 40 mg). Children were subsequently
seen at our outpatient clinic until referral to an adult lipid
clinic or general practitioner for further follow-up.
Ten years after the trial was initiated, we sent all FH
patients a letter that explained the study design of the
current 10-year follow-up study and announced a phone
call within a month. The research physician contacted all
FH patients. Patients who did not agree to participate were
asked for their reasons for non-participation and those
patients who did agree were invited for a single visit to the
Academic Medical Center. One week before this visit we
sent patients a questionnaire including items about medical
history, family history, adherence, reasons for discontinu-
ation, and adverse events. Patients were asked to fill out the
questionnaire at home and take it along to their visit.
During this visit the patients were physically examined
(height, weight, blood pressure) and a fasted blood sample
was taken. The protocol of the study was approved by the
Institutional Review Board and all patients gave informed
consent.
2.2 Blood Analyses
In the fasted blood sample, total cholesterol, high-density
lipoprotein cholesterol (HDL-C) and triglyceride levels
were determined by means of commercially available kits
(Boehringer, Mannheim, Germany). Levels of LDL-C were
calculated with the Friedewald equation [13].
2.3 Outcome Measures
The outcome measures in the current study were tolera-
bility and self-reported adherence to statin therapy after
10 years of treatment. Tolerability was defined as follows:
100 % minus the percentage of patients that discontinued
statin therapy because of side effects. Adherence was
defined as the extent to which patients took their medica-
tion as prescribed by their physician. We assessed
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adherence using the Medication Adherence Self-Report
Inventory (MASRI) and the Medication Adherence Report
Scale (MARS), which have been found to have good reli-
ability and validity and were previously used in patients
with FH [14–16]. Of the MASRI questionnaire, we used
the visual analog scale (VAS) items to determine a numeric
estimate of the adherence rate (0–100 %) in the preceding
week, month, and year. We labelled patients adherent if
they took 80 % or more of their lipid-lowering drugs in the
preceding month [17]. The MARS consists of five state-
ments describing non-adherent behavior: ‘I forget to take
my cholesterol-lowering medication’, ‘I alter the dose of
my cholesterol-lowering medication’, ‘I stop taking my
cholesterol-lowering medication for a while’, ‘I decide to
miss out a dose of my cholesterol-lowering medication’,
and ‘I take less cholesterol-lowering medication than
instructed’. Respondents indicate their degree of agreement
with each statement about medicine taking on a 5-point
Likert scale, ranging from always (1) to never (5). Sum
scores range between 5 and 25 points, with higher scores
indicating higher levels of adherence.
2.4 Statistical Analysis
Continuous variables between subgroups were compared
using the independent sample-t test. Variables with a
skewed distribution were compared by the non-parametric
Mann-Whitney U test. Chi-square tests were applied for
comparing distributions of dichotomous data. We first
explored the association between adherence (yes or no) to
statin therapy after 10 years of treatment and the patient
characteristics (i.e., age, gender, body mass index, LDL-C
at statin initiation, and presence of first degree family
history of CVD), medication use besides lipid-lowering
medication, whether medication was initiated before pub-
erty (defined as before the age of 11.5 years for girls, and
before the age of 13.5 years for boys), and reported side
effects, by means of logistic regression analysis. A multi-
variable model was used to evaluate the independent con-
tributions to the prediction of adherence (yes or no).
Inclusion in the final model was determined by backward
stepwise elimination. A two-sided p value of 0.05 was
considered to indicate statistical significance. All data were




From the original patient cohort of 214 children, nine
subjects (4.2 %) were not available for follow-up because
they refused consent (n = 5) or had moved abroad (n = 2),
and one male adolescent had died after a motorcycle
accident (Fig. 1). One male was excluded, because he had
not completed the questionnaire. Of the remaining 205
subjects, the mean age [±standard deviation (SD)] was
FH patients
N=214
Included in tolerability analyses
N=205 (95.8%)





Died after motor accident (n=1)
Questionnaire not completed (n=1)
Excluded due to pregnancy/lactation (N=13)
Discontinued statin therapy on doctors advice (N=4)
Normalisation of lipid levels (n=2)
Persistant forgetfulness (n=1) 
Interaction with other drugs (n=1)
Fig. 1 Flow chart of familial
hypercholesterolemia (FH)
patients enrolled in the study
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24.0 (±3.2) years and 45.9 % were male. Furthermore, 76
patients (37.1 %) had a family history with CVD in a first-
degree relative. Demographic characteristics and lipid
profiles at the start of the randomized trial and after follow-
up are depicted in Table 1.
Lipid-lowering therapy was still used by 169 (82.4 %)
subjects. Of these, 105 (62.1 %) used statin monotherapy
and another 63 subjects (37.3 %) used statins in combi-
nation with other lipid-lowering drugs, either ezetimibe
(n = 61) or cholestagel (n = 2). One subject received
cholestagel monotherapy. Of the patients using statins, the
majority were still on pravastatin (29.6 %) or had switched
to atorvastatin (28.4 %) (Table 2).
None of the subjects had cardiovascular complaints or a
cardiovascular event during follow-up. The mean (±SD)
number of follow-up visits after the initial trial at the
outpatient clinic by either a (local) lipidologist or general
practitioner was 9.9 (±4.6).
3.2 Tolerability
Three out of 205 patients had completely discontinued drug
therapy due to side effects; i.e., a tolerability of 98.5 %. All
three patients reported a combination of gastro-intestinal
symptoms, muscle and joint pain, or headache. Overall, 55
side effects were reported in the last 10 years by 40
subjects (19.5 %), mainly consisting of muscle complaints
in 19 patients (9.3 %) and gastrointestinal symptoms in 14
patients (6.8 %) (Fig. 2). No major side effects, such as
rhabdomyolysis or elevation of liver enzymes, were
reported.
3.3 Adherence
Current practice is to advise pregnant women with FH to
discontinue all systematically absorbed lipid-lowering
medication; we therefore decided to exclude those patients
who discontinued statin therapy due to current pregnancy
or lactation (n = 13) from the analyses on adherence.
Furthermore, we also excluded four patients who discon-
tinued on the request of their physician. Reasons for those
discontinuations were normalization of lipid levels
(n = 2), interaction with other drugs (n = 1) and persistent
forgetfulness to take medication (Fig. 1). Of the remaining
study group of 188 subjects, 169 patients (89.9 %) used
lipid-lowering medication.
In these 169 FH patients, median [IQR] self-reported
adherence by VAS over the preceding week, month, and
year was 100 % [90–100 %], 95 % [87–100 %] and 90 %
[80–100 %], respectively. Adherence to lipid-lowering
therapy, defined as taking 80 % or more of the prescribed
drugs in the last month, was reported by 148 out of 188
(78.7 %) subjects. Adherent patients had significantly
lower mean (SD) total cholesterol (5.55 ± 1.12 vs













Simvastatin (n = 26)
10 mg – 2 –
20 mg 4 3 –
40 mg 5 11 –
80 mg – 1 –
Pravastatin (n = 50)
20 mg 17 2 –
40 mg 26 3 –
80 mg 1 1 –
Rosuvastatin (n = 44)
10 mg 7 4 –
20 mg 13 7 –
40 mg 7 6 –
Atorvastatin (n = 48)
10 mg 1 – –
20 mg 7 6 –
40 mg 15 11 –
80 mg 2 4 2
Table 1 Patient characteristics and lipid profile in 205 patients with
familial hypercholesterolemia at the start of the randomized clinical
trial and at 10-year follow-up
Start of RCT End of follow-up
Age (years) 13.0 (2.9) 24.0 (3.2)
Initiation before puberty, n (%) 82 (38.3) 79 (38.5)
Male gender, n (%) 100 (47) 94 (46)
Height (cm) 156.3 (14.8) 173.1 (13.4)
Weight (kg) 49.2 (15.3) 74.0 (14.6)
Body mass index (kg/m2) 19.6 (3.6) 24.5 (4.7)
Blood pressure (mmHg)
Systolic 110 (12) 126 (12)
Diastolic 62 (9) 75 (8)
Mean arterial blood pressure 78 (8) 89 (15)
Lipids (mmol/L)
Total cholesterol 7.78 (1.35) 6.24 (1.79)
LDL cholesterol 6.13 (1.31) 4.48 (1.71)




Values are given as mean levels (standard deviation) or otherwise
indicated. Triglycerides are given as median [interquartile range]
HDL high-density lipoprotein, LDL low-density lipoprotein, RCT
randomized clinical trial
162 M. J. A. M. Braamskamp et al.
7.81 ± 1.92 mmol/L, p \ 0.001), LDL-C (3.85 ± 1.03 vs
6.00 ± 1.91 mmol/L, p \ 0.001) and median (IQR) tri-
glyceride levels (0.84 [0.64–1.04] vs 0.95 [0.74–1.26]
mmol/L, p \ 0.001), compared with the non-adherent
group. HDL-C levels did not differ significantly
(1.29 ± 0.35 vs 1.26 ± 0.28 mmol/L, p = 0.62) between
adherent and non-adherent patients (Table 3). In addition,
adherent patients came more frequently to the follow-up
visits as compared with the non-adherent subjects after the
original trial [mean (SD): 10.5 ± 4.5 and 7.6 (±4.3) visits;
p = 0.001, respectively].
Out of the 40 non-adherent subjects (defined as taking
less than 80 % of the prescribed drugs in the last month),
15 patients took between 50 % and 75 % of their medi-
cation. Furthermore, 19 patients (9.3 %) had completely
discontinued statin therapy. Reasons for discontinuation
were as follows: forgotten to take medication (n = 8),
unwillingness to take any medication (n = 6), and side
effects (n = 3). Reasons for discontinuation of therapy for
two patients were unknown.
The results of univariate analysis of the association
between adherence and patient characteristics are shown in
Table 4. No significant associations between any of the
patient characteristics and adherence to statin therapy were
found. Also, in the multivariable analyses after backward
elimination, none of the variables appeared to be inde-
pendently associated with adherence.
More insight in non-adherent behavior was obtained with
MARS questionnaires, consisting of five items on non-
adherent behavior. Responses were skewed with a median
score of 24 (range 5–25); 16.4 % scored 25 (i.e., highly
adherent), 35.3 % scored 24 and 40.4 % scored 23 or less.
Five subjects stated that they always forgot to take their
medication and that they always stopped their medication
for a while. Three subjects stated that they always take less
medication than prescribed. On the question ‘‘I change the
dose prescribed’’, one participant answered ‘‘always true’’,
and on the question ‘‘I decide to skip a dose’’, two patients
indicated this statement to be always true.
4 Discussion
The current study is the first study that assessed tolerability
and adherence of young adult FH patients after long-term
statin therapy that was initiated in childhood. Our findings
indicated that statin therapy was well tolerated; only a
small minority (1.5 %) discontinued therapy because of
side effects and reported side effects were in fact mild. The
vast majority of patients (82.4 %) continued lipid-lowering
therapy, with a high self-reported adherence rate of 78.7 %.
None of the patient characteristics were significantly
associated with adherence.
The use of statin treatment for the prevention of CVD in
patients with FH is supported by extensive clinical
Fig. 2 Number of patients that
had ever experienced side
effects in the last 10 years.
Other: frequent urination (29),
weight reduction, hair loss,
forgetfulness







Total cholesterol 5.55 (1.12) 7.81 (1.92) \0.001
LDL cholesterol 3.85 (1.03) 6.00 (1.91) \0.001
HDL cholesterol 1.29 (0.35) 1.26 (0.28) 0.62
Triglycerides 0.84 [0.64–1.04] 0.95 [0.74–1.26] \0.001
Values are given as mean levels (standard deviation) or otherwise
indicated. Triglycerides are given as median [interquartile range]
HDL high-density lipoprotein, LDL low-density lipoprotein
Table 4 Association between patient characteristics and adherence




Age (years) 1.11 (0.97–1.22) 0.17
Male gender 1.28 (0.63–2.61) 0.49




CVD first-degree family 1.20 (0.58–2.46) 0.62
Use of medication other
than statins
1.39 (0.49–3.90) 0.54
Initiation of statin therapy
before puberty
1.66 (0.77–3.58) 0.20
Side effects 0.54 (0.31–1.87) 0.54
BMI body mass index, CVD cardiovascular disease, LDL low-density
lipoprotein, OR (95 % CI) odds ratio (95 % confidence interval)
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evidence, and the data highlight the safety and tolerability
of statins [18]. Our present study is the longest follow-up
study of patients treated with statins. A follow-up rate as
high as 95.8 % was achieved and patient characteristics of
the non-participants (n = 9) did not differ significantly
from those of the 205 participants at the start of the ran-
domized trial period. No major side effects like elevation
of liver enzymes or rhabdomyolysis had occurred. Analy-
ses by the FDA have reported a rate of fatal rhabdomyol-
ysis of 0.15 per one million statin prescriptions; therefore,
our present sample size is too small to draw conclusions on
the occurrence of rhabdmyolysis or other serious adverse
events [19].
The most frequently discussed side effects of statin
therapy are muscle-related complaints. In our study, we
found 9.3 % of the FH patients have reported to have ever
experienced muscle complaints. Studies on myopathy
related to long-term statin therapy in young adult FH
patients have not been previously reported. Our results are,
however, in line with a large observational study of 7,924
hyperlipidemic patients on high-dose statins in general
practice, aged 18–75 years (PRIMO study). This study
reported an incidence of 10.5 % of mild muscular symp-
toms in the first months after statin therapy was initiated.
These patients were using high doses of statins which
increase the risk of muscular complaints [20]. Two reviews
of more than 35 published clinical trials on patients taking
different kinds of statins reported lower incidences of
myalgia of 1–5 %, which was not significantly different
from the incidence in their placebo group [19, 21]. Inclu-
sion criteria in these statin studies are quite stringent and
patients with a medical history of statin-related side effects
might have been excluded from participation resulting in a
low incidence of myalgia. Mean duration of follow-up
varied extensively between these studies and no consistent
and uniformly applied definition was used; therefore, these
results on muscle-related side effects are difficult to com-
pare with our study. Furthermore, we used questionnaires
to get insight into muscle-related side effects due to statin
treatment. Also, the average age of our patient cohort is
relatively young compared with most other studies and
therefore the patients in our study might be more active and
practising sports and subsequently experience more muscle
complaints.
Adherence to and persistence with statin therapy is
crucial in the management of patients at risk for CVD,
since good adherence and longer duration of persistence
are associated with increasing clinical benefits [22–24]. In
general, persistence rates among patients with chronic
conditions such as FH are quite low, decreasing mainly in
the first 6 months of therapy [25–27]. In our study,
10 years after the start of statin treatment, we found a
remarkably high adherence rate of 78.7 %, defined as those
for whom 80 % or more of days in the last month were
covered by statin therapy. This was further supported by a
high median score of 24 (range 5–25) on MARS state-
ments, indicating that only very few patients showed non-
adherent behavior. Other long-term follow-up studies
evaluating adherence to statin therapy in primary preven-
tion indicated adherence rates as low as 39 % after 3 years
of treatment. These trials have been conducted in elderly
non-FH patients, who initiated treatment at the mean age of
56 years and older [26, 27]. These results are therefore
difficult to compare with our young adult population using
statins as primary prevention from childhood onwards. Our
study subjects initiated statin therapy in childhood during a
clinical trial, with regular visits (i.e., every 3 months) to
our outpatient clinic. This early initiation of treatment and
close monitoring might contribute to habitual use of statins
and therefore better adherence to therapy. However,
patients’ self-reported statin use was acquired to determine
their adherence. This method might be susceptible to
inaccurate patient recall or social desirability and might
lead to an overestimation of adherence. However, adherent
patients had significantly lower cholesterol levels than non-
adherent patients, an effect that cannot be explained by a
difference in untreated cholesterol levels.
As in all randomized controlled trials, stringent inclu-
sion and exclusion criteria were applied, essentially
excluding the sickest and frailest people, which could limit
the generalizability of our results. However, FH children
were enrolled in the trial between 1997 and 1999 and at
that time the Academic Medical Center was the only clinic
in The Netherlands and one of the very few clinics
worldwide that treated these children. As a consequence,
children with FH were referred from all over the country to
our lipid clinic and from that point of view the children
included in our study are a reasonable representative of the
general population with this disorder.
The main reason for discontinuation of therapy in our
study group was pregnancy, which is in accordance to
current medical advice. Non-adherence in our cohort was
accompanied by significantly higher LDL-C levels and a
lower out-patient follow-up frequency. Reasons for non-
adherence were unwillingness to take medication and for-
getfulness. According to the literature, non-adherence is
associated with younger age, female gender, lower socio-
economic status and complex treatment regimen [6, 28,
29]. Although we did not have information on socio-eco-
nomic status, our results did not reveal significant associ-
ations between these or any of the other factors and
adherence to statin therapy.
Current practice in FH patients is to achieve LDL-C
reduction of at least 50 % and preferably LDL-C levels
below 2.5 mmol/L [30]. Neither of these treatment goals
have been reached in our study group. Despite a good
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adherence rate of 78.7 % in our cohort, the mean LDL-C
level of the adherent group was still 3.85 mmol/L, and only
eight patients had LDL-C levels \2.50 mmol/L. Our
results are in line with those of Pijlman et al. [31], who
conducted a cross-sectional study among adult FH patients
in the Netherlands and concluded that only 21 % of the
1,249 patients reached the treatment goal for LDL-C of
\2.5 mmol/L. This raises serious concerns on the risk of
future cardiovascular events and therefore treatment regi-
mens for this patient group should be improved in the
future.
In conclusion, this study demonstrates that patients with
FH who started statin therapy in childhood, regardless
whether this was before or after puberty, showed good
adherence during 10 years of treatment. The fact that early
initiation may contribute to habitual use of medication
despite its preventive character, and the fact that none of
the patients had suffered from cardiovascular disease are
important clinical findings. Even more important, statin
therapy was very well tolerated; only a very small minority
discontinued therapy because of side effects, and reported
side effects were mild. However, their treatment appeared
to be suboptimal in terms of efficacy and this merits further
attention.
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